Stemtech Q2 FY26 net loss narrows 1.32% to $292,358; net sales fall 9.8% to $629,312
STEK•Quarterly results
Stemtech posted a net loss of $292,358 for Q2 ended June 30, 2026, narrowing from $296,280 a year earlier.
Net sales fell 9.8% to $629,312 on constrained product availability across key lines that limited distributor order fulfillment.
Margins and expenses
Operating loss narrowed to $125,567 from $300,988 as operating expenses dropped to $591,240 from $853,004.
Gross margin slid 5.1 percentage points to 74% as mix worsened, with fixed fulfillment and freight costs weighing.
E-commerce platform launch
The February launch of the Stemtech BioSciences e-commerce platform targets broader retail distribution and greater direct consumer access.
